Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Inovio Biomedical Corporation
Inovio Biomedical and VGX Pharmaceuticals Stockholders Overwhelmingly Approve Proposed Merger
June 17th, 2009
Inovio Biomedical Corporation (NYSE Amex: INO) and VGX Pharmaceuticals, Inc. announced that stockholders of both companies approved the previously announced proposed merger of Inovio and VGX. The combination of DNA vaccine development expertise, clinical pipeline, electroporation-based DNA delivery technology and robust patents will position the combined company as a leading DNA vaccine discovery, development, and delivery company. At a special meeting of Inovio stockholders held today, 80.7% of total votes cast were voted in favor of the business combination. At a special meeting of VGX stockholders held today, 99.7% of total votes cast were voted...
Source: Vaccine Weekly (2009-06-17)
|
